News regarding the healthcare sector and Fresenius Kabi

Medical Nutrition | May 14, 2025

Perioperative Medical Nutrition: Expert Surgical Tips

Discover best practices in perioperative nutrition from leading surgical experts. Four podcast episodes on surgery and nutrition management.

Press Release | May 7, 2025

Fresenius Q1/25: Strong Start to 2025 – #FutureFresenius Rejuvenate Phase Kicked-off With Excellent Momentum

Q1/2025: Strong top line and excellent EPS growth, outlook confirmed

Medical Nutrition | April 14, 2025

Lizl Veldsman receives prestigious Harry M. Vars Award

Lizl Veldsman from South Africa wins the award for her study on preventing muscle loss in ICU patients, supported by Fresenius Kabi's research grant.

Press Release | April 9, 2025

Fresenius makes progress on streamlining its production network

Fresenius Kabi optimizes production network: Fresenius Kabi and EMS have signed an agreement to transfer the ownership of Fresenius Kabi's production site in Anápolis, Brazil, to EMS.

Biopharma | March 26, 2025

Fresenius receives FDA approval for their Denosumab biosimilars and secures global settlement agreement

Fresenius announced that the Biologics License Application (BLA) for the denosumab biosimilars Conexxence®** (denosumab-bnht) and Bomyntra®** (denosumab-bnht) of its operating company Fresenius Kabi has been approved by the FDA.

Gloved hand holding a conical flask with blue liquid in a laboratory setting, surrounded by glassware and scientific equipment

Strategy | March 25, 2025

Fresenius FY/24: Strong Fourth Quarter concludes successful Fiscal Year; Fresenius moving to next level of performance with #FutureFresenius Rejuvenate phase

FY/24: Upgraded outlook achieved, consistent financial performance with profitable growth.

Medical Nutrition | February 25, 2025

Advancing clinical nutrition research: The JUMPstart program enters its fourth wave

With this mentoring program, Fresenius Kabi supports early-career clinicians and researchers through education, networking, and funding opportunities.

Medical Nutrition | January 29, 2025

Fresenius Kabi and ESICM Renew Joint Collaboration for 2025

To further advance research and medical education in the field of intensive care medicine, Fresenius Kabi continues its collaboration with ESICM in 2025.

MedTech | January 28, 2025

Fresenius Receives FDA 510(k) Clearance for Adaptive Nomogram, Enhancing Plasma Collection Efficiency

Fresenius, via its operating company Fresenius Kabi, announced today that the U.S. FDA has granted 510(k) clearance to its Adaptive Nomogram.

Strategy | January 16, 2025

Fresenius Kabi Earns Top Employer Certification in 12 Countries

Fresenius Kabi is a Top Employer in 2025, with twelve countries receiving certification from the Top Employers Institute.

Biopharma | December 19, 2024

Fresenius to Expand Biopharma Portfolio With a New Licensing Agreement to Commercialize a Proposed Aflibercept Biosimilar

Fresenius, through its operating company Fresenius Kabi, is broadening its growing biopharma portfolio through a new licensing agreement with South Korea’s SamChunDang Pharm (SCD).

Pharma | December 17, 2024

Fresenius Launches First 1mg/1 mL Generic Version of Epinephrine in the U.S.

Fresenius, through its operating company Fresenius Kabi, announced today that Epinephrine Injection, USP, is now available in the United States.

Young chemist arranging medicines on shelf. Female pharmacist is working in pharmacy. She is standing in medical store.

MedTech | December 10, 2024

Ori Biotech and Fresenius Kabi Collaborate to Advance Modular, Scalable Manufacturing of Cell and Gene Therapies

New collaboration showcases successful integration of Ori's IRO Platform with Cue and Lovo processing systems to enhance efficiency in CGT manufacturing

People | November 20, 2024

Fresenius Kabi helps raise awareness for the growing global threat of antimicrobial resistance

By increasing awareness of responsible antibiotic use, Fresenius Kabi is helping to improve patient outcomes and reduce the risk of antimicrobial resistance.

Press Release | November 6, 2024

Fresenius Q3/24: Simplification and Focus Drives Sustained Performance – Outlook Upgraded

Michael Sen, CEO of Fresenius: "Team Fresenius delivered an excellent third quarter in 2024 – all financial metrics improved versus the prior year."

People | October 31, 2024

Empowering Women: How Tanya and Bela lead Breast Cancer Awareness through the Women’s VOICE EIG

Discover how Tanya and Bela lead the Women’s VOICE EIG in the U.S., empowering women and raising awareness about breast cancer through advocacy and support.

Sustainability | October 17, 2024

Celebrating Innovation

Fresenius Kabi wins prestigious sustainability award at Berlin’s Sustainability Kongress 2024 for innovative CO₂ reduction project at Friedberg manufacturing plant.

MedTech | October 16, 2024

Cellular Origins, Fresenius Kabi Sign Development Agreement for Scalable Automation of Cell and Gene Therapy Manufacturing

Development agreement signed to leverage expertise and support cell therapy developers in the large-scale production of their therapies.

Medical Nutrition | October 8, 2024

Fresenius Kabi continues to partner with researchers to improve patient care

The winner of the Fresenius Kabi Clinical Nutrition Award, Dr. Sandra Emily Stoll from Cologne, Germany, has received the €20,000 research grant at ESICM 2024.

Biopharma | September 30, 2024

Fresenius Kabi and Formycon Receive U.S. FDA Approval for Biosimilar OtulfiTM* (ustekinumab-aauz)

Otulfi™ received FDA approval for both subcutaneous and intravenous formulations, to treat the same conditions as Stelara®.

Close up of a scientist with protective gloves working with samples in a lab. AI generative

Biopharma | September 27, 2024

Otulfi®*, Fresenius Kabi’s Ustekinumab Biosimilar Developed by Formycon, Receives European Commission Approval

Otulfi® received European Commission (EC) approval for both subcutaneous and intravenous formulations, providing a high-quality treatment option for European patients treated with ustekinumab

hand of scientist holding flask with lab glassware in chemical laboratory background, science laboratory research and development concept

Medical Nutrition | September 26, 2024

Advancing Medical Nutrition: Fresenius Kabi at ESPEN 2024

Fresenius Kabi showcases commitment to improving patient care through holistic expertise in medical nutrition and its innovative solutions at ESPEN.

People | September 25, 2024

Queen Silvia Nursing Award for Innovative Dementia Care Platform

Paola Gava, a nursing student from Germany, was honored with the Queen Silvia Nursing Award for her innovative dementia care online platform, MED-DEM.

Pharma | September 17, 2024

Advancing Patient Safety through Digital Innovation

Innovative digital technology like data matrix barcodes or RFID labels is streamlining inventory processes in hospitals, ultimately contributing to patient safety

People | August 28, 2024

Supporting Brazilian Athletes Achieve Their Dreams at the 2024 Paralympics

Fresenius Kabi is a sponsor of the Athlon Institute in São José dos Campos, Brazil, which is sending 20 athletes to the 2024 Paralympics.

Press Release | August 5, 2024

Fresenius Kabi Receives 2024 Trailblazer Award From Premier Inc. For Supply Chain Innovation

This award recognizes a Premier Inc. national contracted supplier that uses or deploys innovative and scalable methods and technology to accelerate clinical evidence into real-world practice.

Press Release | July 31, 2024

Fresenius With Excellent Performance in Q2; Major Progress on Deleveraging on the Back of Strong Cash Flow: Entering Target Ratio Corridor; Outlook Confirmed and Optimistic About Second Half

Major progress on deleveraging on the back of strong cash flow: entering target ratio corridor; outlook confirmed and optimistic about second half.

Biopharma | July 26, 2024

Fresenius Kabi and Formycon Receive Positive CHMP Opinion for FYB202, an Ustekinumab Biosimilar Candidate

Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommends approval of FYB202 for the treatment of severe inflammatory diseases.

Biopharma | July 11, 2024

Fresenius Announces EMA Validation of Marketing Authorization Application for Denosumab Biosimilar Candidates

European Medicines Agency has accepted for review the Marketing Authorization Applications for the biosimilar candidates of Prolia® (denosumab) and Xgeva® (denosumab)

Sustainability | July 5, 2024

Ideas for a Better Tomorrow

The Championship Day is a competition for our employees to drive positive change. Many ideas that are improving our environmental performance are implemented.

Biopharma | July 2, 2024

Fresenius Continues its Biopharma Momentum with Launch of Subcutaneous Formulation of Tyenne® (tocilizumab-aazg) in the United States

The subcutaneous formulation of the tocilizumab biosimilar provides increased access and an affordable treatment option for U.S. patients.

Close Up Of Female Lab Worker Wearing PPE And Safety Glasses Looking At Slide Under Microscope

MedTech | June 14, 2024

Giving Life, One Donation at a Time

Celebrate World Blood Donor Day with Fresenius Kabi. Discover our global impact on blood donation and how we’re saving lives, one drop at a time.

MedTech | June 3, 2024

New Whitepaper: Infusion Systems & Interoperability in Healthcare Information Systems

Read our new whitepaper on Infusion Systems and Interoperability in Healthcare Systems – A perspective in use cases and an analysis of applicable standards

Biopharma | May 27, 2024

Fresenius Announces U.S. FDA Acceptance for Review of Biologics License Application for Denosumab Biosimilar Candidate

U.S. Food and Drug Administration has accepted for Review of Biologics License Application for our Denosumab Biosimilar Candidate

Young clinician looking at flask with liquid, Young clinician looking at flask with liquid

Press Release | May 8, 2024

Fresenius Raises Outlook for Fiscal 2024 Due to Excellent First Quarter

Group outlook raised for FY/24 due to the excellent first quarter and a better than originally expected operating performance for the remainder of the financial year 2024.

Medical Nutrition | April 25, 2024

Jumpstart Clinical Nutrition Program 2024: Nurturing and Connecting Rising Stars in Clinical Nutrition

Join our clinical nutrition program for research, mentorship, and a chance to win a €250,000 grant.

Biopharma | April 15, 2024

Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne®*, its Third Approved Biosimilar in the U.S.

Medical Nutrition | April 9, 2024

JUMPstart Renal Nutrition Therapy Program: Application phase now open

Fresenius Kabi has launched the JUMPstart Renal Nutrition Therapy Research Program to facilitate more studies in nutritional interventions for CKD.

Biopharma | March 18, 2024

Fresenius Kabi and Formycon reach settlement agreement for ustekinumab biosimilar candidate

Fresenius Kabi and Formycon have reached a settlement agreement with Johnson & Johnson for FYB202, a proposed ustekinumab biosimilar to Stelara in Europe and Canada.

Biopharma | March 7, 2024

Fresenius Kabi’s Biosimilar Tyenne® (tocilizumab-aazg) Becomes the First IV and Subcutaneous Tocilizumab Biosimilar Approved by the FDA

Tyenne® becomes Fresenius Kabi's first tocilizumab biosimilar with both IV and subcutaneous formulations approved by the FDA.

Press Release | March 1, 2024

Fresenius Kabi completes divestment of its Halden, Norway, plant

Fresenius Kabi and Prange Group have completed the transfer of ownership of the former Fresenius Kabi plant in Halden, Norway, to HP Halden Pharma AS.

Medical Nutrition | February 28, 2024

Empowering Healthcare Innovation: Fresenius Kabi and ESICM Continue Collaboration

To further foster research and medical training in intensive care, we continue our collaboration with the European Society for Intensive Care Medicine.

Press Release | February 21, 2024

Fresenius Closes 2023 With a Strong Fourth Quarter and Expects Accelerated Earnings Growth in 2024 Through Increasing Momentum From #FutureFresenius

Fresenius achieves its raised FY/23 outlook with a strong final quarter. Read more about Fresenius' fourth quarter performance and strategic priorities in 2024.

Medical Nutrition | February 15, 2024

A Year of Achievements and Global Collaboration With JUMPstart Clinical Nutrition Alumni Program

Experience the continued growth and collaboration within the JUMPstart alumni community. Discover the past activities and find out what awaits you in 2024.

Strategy | January 18, 2024

A Continuation of Excellence as a Top Employer in 2024

Fresenius Kabi is a Top Employer in 2024, with nine countries receiving certification from the Top Employers Institute.

MedTech | December 14, 2023

Fresenius Kabi and Mayo Clinic Enter into Multiyear Supply and Service Agreement for the Ivenix® Infusion System

Fresenius Kabi and Mayo Clinic have signed a multiyear contract for the Ivenix Infusion System. Learn how this collaboration impacts the healthcare sector.

Biopharma | November 30, 2023

Fresenius Kabi and Formycon Announce FDA Submission Acceptance for Review for Ustekinumab Biosimilar Candidate

Announcement of Fresenius Kabi and its license partner Formycon: FDA has accepted Ustekinumab biosimilar candidate for review.

Pharma | November 23, 2023

Safeguarding Tomorrow: Our Commitment to Fight Antimicrobial Resistance

Fresenius Kabi, one of the leading manufacturers of intravenously administered generic antibiotics, takes active measures to fight antimicrobial resistance.

Press Release | November 2, 2023

#FutureFresenius Continues to Provide Positive Momentum

Fresenius delivers strong third quarter performance and improves operating earnings outlook

Biopharma | November 1, 2023

Fresenius Kabi Launches Tyenne®*, the First Approved Tocilizumab Biosimilar in the European Union

Tyenne® becomes the first tocilizumab biosimilar available in Europe for the treatment of several inflammatory and immune diseases.

Medical Nutrition | October 31, 2023

Supporting Conscious Choices in Nutritional Care

Demands for plant-based alternatives: Fresubin® Plant-Based supports individuals with or at risk of malnutrition, while respecting dietary preferences.

Medical Nutrition | October 25, 2023

Gastrointestinal Dysfunction Study Wins Inaugural ESICM Clinical Nutrition Award

Fresenius Kabi is excited to announce that Prof. Arthur van Zanten, MD Ph.D., is the recipient of the € 20,000 grant at the ESICM Clinical Nutrition Award

Biopharma | September 29, 2023

Fresenius Kabi and Formycon Announce EMA Submission Acceptance of the Marketing Authorization Application for FYB202, an Ustekinumab Biosimilar Candidate

Fresenius Kabi and its license partner Formycon AG announce that the European Medicines Agency has accepted the Marketing Authorization Application for FYB202.

Biopharma | September 19, 2023

Tyenne®*, Fresenius Kabi’s Tocilizumab Biosimilar, Receives European Commission Approval

Fresenius Kabi announced that the European Commission (EC) granted marketing authorization for its tocilizumab biosimilar Tyenne®.

People | September 15, 2023

Fresenius Kabi Recognized as a Top Employer in 2023

Fresenius Kabi is a Top Employer, with six countries receiving certification from the Top Employers Instititute.

MedTech | September 14, 2023

Virginia Oncology Associates Chooses the Ivenix Infusion System from Fresenius Kabi

Fresenius Kabi has signed an agreement with Virginia Oncology Associates to purchase the Ivenix Infusion System to deliver medications for its patients.

Medical Nutrition | September 13, 2023

Jumpstart Clinical Nutrition Award Winner Announced at ESPEN Congress

Fresenius Kabi’s JUMPstart Clinical Nutrition Award winner is announced at ESPEN congress: Lee Zheng Yii receives 250,000 Euro research grant for his fish oil nutrition study.

MedTech | August 24, 2023

Fresenius Kabi and Lupagen Enter Into Strategic Development and Supply Agreement to Bring Cell and Gene Therapies to the Bedside

Fresenius Kabi and Lupagen Inc. have entered into an agreement for technologies designed to bring the delivery of cell and gene therapies closer to the patient.

MedTech | August 17, 2023

Paving the Way for the Future of Blood Transfusions

Recently launched blood bag system not made with DEHP addresses market needs and is subject of an award-winning clinical study.

Biopharma | August 7, 2023

Fresenius Kabi and Formycon Secure U.S. License Date for Proposed Ustekinumab Biosimilar

Fresenius Kabi and Formycon AG entered into a settlement agreement with Johnson & Johnson concerning FYB202, a proposed ustekinumab biosimilar in the U.S.

MedTech | August 4, 2023

Heroes Who Save Lives: A Heartfelt Thank You to All Blood and Plasma Donors

Explore the incredible impact of blood donation. Watch what our heroes think about during blood or plasma donation and read about our blood donation events.

Press Release | August 2, 2023

Progress on #FutureFresenius

Operating Companies Showing Consistent Performance; Group Simplification Delivered

Biopharma | July 21, 2023

Fresenius Kabi’s Tocilizumab Biosimilar Candidate MSB11456 Receives Positive CHMP Opinion

Fresenius Kabi’s tocilizumab biosimilar candidate MSB11456 receives positive CHMP opinion.

Biopharma | July 12, 2023

Fresenius Kabi’s Denosumab Biosimilar Candidate FKS518 Shows Positive Clinical Trial Results

Fresenius Kabi’ denosumab biosimilar candidate FKS518 shows positive clinical trial results.

Biopharma | July 2, 2023

Fresenius Kabi Launches Its Citrate-Free Biosimilar Idacio® (adalimumab-aacf) In the United States

Fresenius Kabi announced today the launch of its citrate-free biosimilar Idacio (adalimumab-aacf).

MedTech | June 14, 2023

The Gift of Life: A Decision to Donate Blood or Plasma

Today is World Blood Donor Day - find out more about the constant need for blood and plasma donations and watch the interview with Pierre Vidal.

Strategy | May 25, 2023

Fresenius SE Hosts Kabi Capital Markets Day Outlining Pathway Towards Sustainable Value Creation in Line With #FutureFresenius

Fresenius SE hosts Kabi Capital Markets Day Event, presenting the future path towards a sustainable value creation and strategies for #FutureFresenius.

MedTech | May 23, 2023

Fresenius Kabi Awarded Breakthrough Technology Agreement With Premier, Inc. For the Ivenix Infusion System

Fresenius Kabi secures Premier's Technology Breakthrough agreement, reinforcing their unwavering dedication to innovation and excellence in healthcare.

Pharma | May 17, 2023

Fresenius Kabi at the Euroanaesthesia 2023

Fresenius Kabi will be present at the Euroanaesthesia 2023 with a booth and symposium about best practice for ICU sedation and sustainable anesthesia.

Medical Nutrition | May 15, 2023

Fresenius Kabi Offers €100,000 Grant to Advance Nutritional Care in Hospitalized Patients

Fresenius Kabi fuels nutritional research with a $100,000 grant, driving innovation in the field. Explore the steadfast commitment to advancement now.

Press Release | May 9, 2023

Fresenius Executing on #FutureFresenius

Strong Performance Of Operating Companies in Q1/23 and Structural Simplification on Track

People | May 4, 2023

Help for Communities in Crisis

Watch a video about Fresenius Kabi's humanitarian efforts in ongoing earthquake relief initiatives through the donation of essential medical supplies.

MedTech | April 24, 2023

Fresenius Kabi Launches Single-Needle Option for the Amicus® Extracorporeal Photopheresis Protocol

Fresenius Kabi introduces a single-needle venous access option for the Amicus® Extracorporeal Photopheresis System, enhancing healthcare possibilities.

MedTech | April 17, 2023

Vizient Innovative Technology Contract Awarded to Fresenius Kabi for the Ivenix Infusion System

Vizient Innovative Technology contract awarded to Fresenius Kabi for the Ivenix infusion system. The contract sets terms for hospitals to buy the system.

People | March 3, 2023

Fresenius Kabi Provides Humanitarian Aid for Ukraine

Fresenius Kabi's compassionate humanitarian aid for Ukraine, showcasing their unwavering commitment to assisting those in need during challenging times.

Press Release | February 22, 2023

Fresenius Strengthens Its Management Board Team – New Appointment at Fresenius Kabi – Expansion of Human Resources/Legal to Include ESG

Fresenius strengthens its management board team with new appointments at Fresenius Kabi and an expansion of the Human Resources and Legal department.

Strategy | February 21, 2023

Fresenius With New Strategy and Clear Focus

Fresenius sets a new direction for the future with new strategies and a new, rigorous financial framework in its press report for the fiscal year 2022.

Biopharma | February 16, 2023

Fresenius Kabi Launches Biosimilar Stimufend® (pegfilgrastim-fpgk) in the U.S.

Fresenius Kabi announces the launch of pegfilgrastim biosimilar Stimufend® in the U.S., expanding access to quality healthcare solutions against cancer.

Medical Nutrition | February 11, 2023

International Day of Women in Science: an Interview with JUMPstart Winner Lizl Veldsman

Get inspired by Lizl Veldsman, JUMPstart winner 2019 with her research project on clinical nutrition and read her advices for future female researchers.

People | February 10, 2023

Fresenius Expresses Deepest Sympathies and Commitment to Support Earthquake Victims in Türkiye and Syria

The Fresenius Group sends its deepest symphaties and condolences to people affected by the earthquake in Türkiye and Syria and donates lifesaving products.

MedTech | February 9, 2023

Ivenix Infusion System Receives Glowing Review by KLAS Research

Ivenix Infusion System is the subject of a recent KLAS report, showing that U.S. customers are highly satisfied with the technologically advanced system.

Biopharma | February 2, 2023

Fresenius Kabi announces global license agreement with Formycon AG to commercialize proposed Ustekinumab biosimilar

Fresenius Kabi and Formycon partner globally to commercialize Ustekinumab biosimilar, expanding access to affordable healthcare solutions worldwide.

People | January 24, 2023

Waterproof Zip Toiletry Bag Wins Queen Silvia Nursing Award Germany 2022

Sonja Meyers idea "getAgo" a waterproof zip toiletry bag wins the queen silvia nursing award in spring 2023. Read more about the award and her idea here.

Strategy | January 4, 2023

Vision 2026 – Fresenius Kabi’s Healthy Growth Journey

To remain a responsible and successful company, Fresenius Kabi's Vision 2026 is the foundation for a sustainable growth strategy for the next decade.

Biopharma | December 14, 2022

Fresenius Kabi receives U.S. FDA approval for biosimilar Idacio® (adalimumab)

Fresenius Kabi gets U.S. FDA approval for their biosimilar Idacio®, a citrate-free formulation of adalimumab which use is for chronic autoimmune diseases.

Medical Nutrition | December 12, 2022

JUMPstart 2022 – Committed to Driving Research in Clinical Nutrition

MedTech | November 16, 2022

A Continuous Success Story: Fresenius Kabi Inaugurates Extension of Its Production Facilities in Haina

Fresenius Kabi achieves new important milestone with the extension of the 4th MedTech manufacturing facility at PIISA in Haina in the Dominican Republic.

Press Release | October 30, 2022

Fresenius With Weak Third Quarter Driven by Ongoing Challenging Macroeconomic Environment – FY/22 Guidance Revised – Charting a New Course for Fresenius

Weak third quarter for Fresenius Kabi due to ongoing challenging macroeconomic enviroment. Fresensius responds with realignment of business activities.

People | October 26, 2022

Fresenius Kabi Employees Around the World Team Up for Breast Cancer Awareness

Fresenius Kabi employees in the US, Italy, France, Haina, Brasil and more have shown their commitment for Breast Cancer Awareness Month in different ways.

Strategy | October 3, 2022

Our New Fresenius CEO Michael Sen Outlines What Will Be Essential for #FutureFresenius

New Fresenius CEO Michael Sen outlines his vision for #FutureFresenius and his initial thoughts on the project in a video from the 3rd of october 2022.

People | September 28, 2022

Learning and Creativity for Little Patients at Children’s Cancer Hospital

Explore how Fresenius Kabi supports young patients and their families with creative learning experiences about nutritions at Children's Hospital in Cairo.

Biopharma | September 6, 2022

Fresenius Kabi receives U.S. FDA approval for biosimilar Stimufend® (pegfilgrastim)

Fresenius Kabi announces that the FDA has approved its pegfilgrastim biosimilar, Stimufend® which is a high-quality treatment option for cancer patients.

Press Release | August 19, 2022

Michael Sen to Succeed Stephan Sturm as CEO of Fresenius

Fresenius appoints Michael Sen as the successor of the former CEO Stephan Sturm. He will take up his new position at the beginning of October 2022.

Biopharma | August 18, 2022

Fresenius Kabi Announces Acceptance of its Marketing Authorization Application by the European Medicines Agency for MSB11456, a Tocilizumab Biosimilar Candidate

Fresenius Kabi announces EMA acceptance for biosimilar MSB11456, which is a new addition to a compelling biosimilar portfolio against autoimmune diseases.

Biopharma | August 10, 2022

Fresenius Kabi Establishes Partnership With Bio-Manguinhos/Fiocruz and Bionovis to Provide Access to Adalimumab Biosimilar in Brazil

Fresenius Kabi announces a partnership with Fiocruz/Bio-Manguinhos for the production of adalimumab biosimilar, IDACIO in Brazil for autoimmune diseases.

Press Release | August 2, 2022

Fresenius Publishes Financial Results for the Second Quarter and First Half of 2022 in Line With Preliminary Results

Preliminary and financial results for the second quarter and first half of 2022 and more on how Fresenius Kabi is meeting the overall economic challenges.

Biopharma | August 1, 2022

Fresenius Kabi’s Biologics License Application for Biosimilar Candidate Tocilizumab Accepted for Review by the FDA

The FDA has accepted for review Fresenius Kabi’s Biologics License Application for the company’s biosimilar candidate of tocilizumab.

Biopharma | August 1, 2022

Fresenius Kabi Completes Majority Stake Acquisition of mAbxience Holding S.L., Significantly Enhancing Presence in High-Growth Biopharmaceuticals Market

Fresenius Kabi's successful majority stake acquisition of mAbxience marks a significant step in their commitment to healthcare innovation and excellence.

Press Release | July 27, 2022

Fresenius Revises FY/22 Group Guidance Driven by Significantly Worsening Headwinds at Fresenius Medical Care - Outlook Confirmed For Fresenius Kabi, Fresenius Helios and Fresenius Vamed

Fresenius Kabi revises outlook for group guidance 2022 due to increased wage inflation, labor shortage and overall worsened macrooeconomic enviroment.

People | July 25, 2022

The Austrian Broadcasting Corporation (ORF) Portrayed “The Future Makers” at Fresenius Kabi Austria

Explore, what the Austrian broadcasting cooperation's video shoot for its series "The future makers" was like and get an insight into the Styrian industry.

MedTech | July 4, 2022

Ten Years of Blood Donation Activity Across China – Committed to Life at Its Best

For ten years Fresenius Kabi China organises nationwide blood donation activities with an increasing number. Our promise Committed to Life at its best.

People | June 9, 2022

Further Donations to Support Emergency Care of Patients in Ukraine

Fresenius Kabi continues its efforts to provide humanitarian aid to Ukraine and recently donated about 70 pallets of urgently needed lifesaving medicines.

Medical Nutrition | May 23, 2022

EuroPN Study: New Clinical Data on Medical Nutrition Therapy in Critically Ill Patients

New data from the EuroPN study shows that early medical nutrition therapy with moderate daily calorie and protein intakes improves clinical outcomes.

Press Release | May 4, 2022

Fresenius With Solid Start to 2022 Despite Macroeconomic Challenges

Successful start for Fresenius Kabi in 2022, despite macrooeconomic challenges – Read all information about financial growth and market developements.

MedTech | May 4, 2022

Fresenius Kabi completes acquisition of Ivenix, Inc., creating an industry-leading infusion therapies offering in the U.S.

Fresenius Kabi completes the acquisition of Ivenix which provides state-of-the-art and industry leading offerings in infusion therapy for the U.S market.

MedTech | May 3, 2022

Fresenius Kabi Prolongs the Production and Supply Contract With Cerus Corporation for an Additional 10 Years

Fresenius Kabi and the U.S. company Cerus Corporation signed a new agreement for the production of systems for pathogen inactivation in blood components.

Press Release | March 31, 2022

Next generation patient care: Fresenius Kabi buys a majority stake in mAbxience and acquires Ivenix

Fresenius Kabi buys a majority stake in mAbxience and acquires Ivenix which significantly enhances their presence in high-growth biopharmaceuticals market.

Biopharma | March 30, 2022

Fresenius Kabi Receives European Commission Approval for Its Pegfilgrastim Biosimilar Stimufend®

Fresenius Kabi announces that the European Commission granted marketing authorization for Stimufend® which offers a high-quality option for cancer patients.

People | March 18, 2022

Update on Humanitarian Aid for Ukraine

Read about the current status of humanitarian aid for Ukraine and Fresenius Kabi's contribution to the emergency treatment and care of patients on site.

Press Release | February 22, 2022

Fresenius Delivers a Strong Finish to the Year Meeting Its Improved 2021 Guidance – Strategic Evaluation Shows Path to Accelerated Growth

Successful annual financial statements and positive outlook for fiscal year 2022 for Fresenius Kabi – Strategic evaluation shows path to accelerated growth.

Vision

Excellence

Sustainability

News

Perioperative Medical Nutrition: Expert Surgical Tips

Fresenius Q1/25: Strong Start to 2025 – #FutureFresenius Rejuvenate Phase Kicked-off With Excellent Momentum

Lizl Veldsman receives prestigious Harry M. Vars Award

Fresenius makes progress on streamlining its production network

Fresenius receives FDA approval for their Denosumab biosimilars and secures global settlement agreement

Fresenius Kabi Hosts Over 100 Global Experts at FRANC Oncology Conference

Keep an Eye on Their Back

Continuing Biopharma Growth with U.S. and EU Launch of Ustekinumab Biosimilar

Fresenius FY/24: Strong Fourth Quarter concludes successful Fiscal Year; Fresenius moving to next level of performance with #FutureFresenius Rejuvenate phase

Advancing clinical nutrition research: The JUMPstart program enters its fourth wave

Fresenius Kabi and ESICM Renew Joint Collaboration for 2025

Fresenius Receives FDA 510(k) Clearance for Adaptive Nomogram, Enhancing Plasma Collection Efficiency

Fresenius Kabi Earns Top Employer Certification in 12 Countries

Fresenius to Expand Biopharma Portfolio With a New Licensing Agreement to Commercialize a Proposed Aflibercept Biosimilar

Fresenius Launches First 1mg/1 mL Generic Version of Epinephrine in the U.S.

Ori Biotech and Fresenius Kabi Collaborate to Advance Modular, Scalable Manufacturing of Cell and Gene Therapies

Fresenius Kabi helps raise awareness for the growing global threat of antimicrobial resistance

Fresenius Q3/24: Simplification and Focus Drives Sustained Performance – Outlook Upgraded

Empowering Women: How Tanya and Bela lead Breast Cancer Awareness through the Women’s VOICE EIG

Celebrating Innovation

Cellular Origins, Fresenius Kabi Sign Development Agreement for Scalable Automation of Cell and Gene Therapy Manufacturing

Fresenius Kabi continues to partner with researchers to improve patient care

Fresenius Kabi and Formycon Receive U.S. FDA Approval for Biosimilar OtulfiTM* (ustekinumab-aauz)

Otulfi®*, Fresenius Kabi’s Ustekinumab Biosimilar Developed by Formycon, Receives European Commission Approval

Advancing Medical Nutrition: Fresenius Kabi at ESPEN 2024

Queen Silvia Nursing Award for Innovative Dementia Care Platform

Advancing Patient Safety through Digital Innovation

Supporting Brazilian Athletes Achieve Their Dreams at the 2024 Paralympics

Fresenius Kabi Receives 2024 Trailblazer Award From Premier Inc. For Supply Chain Innovation

Fresenius With Excellent Performance in Q2; Major Progress on Deleveraging on the Back of Strong Cash Flow: Entering Target Ratio Corridor; Outlook Confirmed and Optimistic About Second Half

Fresenius Kabi and Formycon Receive Positive CHMP Opinion for FYB202, an Ustekinumab Biosimilar Candidate

Fresenius Announces EMA Validation of Marketing Authorization Application for Denosumab Biosimilar Candidates

Ideas for a Better Tomorrow

Fresenius Continues its Biopharma Momentum with Launch of Subcutaneous Formulation of Tyenne® (tocilizumab-aazg) in the United States

Giving Life, One Donation at a Time

New Whitepaper: Infusion Systems & Interoperability in Healthcare Information Systems

Fresenius Announces U.S. FDA Acceptance for Review of Biologics License Application for Denosumab Biosimilar Candidate

Fresenius Raises Outlook for Fiscal 2024 Due to Excellent First Quarter

Jumpstart Clinical Nutrition Program 2024: Nurturing and Connecting Rising Stars in Clinical Nutrition

Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne®*, its Third Approved Biosimilar in the U.S.

JUMPstart Renal Nutrition Therapy Program: Application phase now open

Fresenius Kabi and Formycon reach settlement agreement for ustekinumab biosimilar candidate

Fresenius Kabi’s Biosimilar Tyenne® (tocilizumab-aazg) Becomes the First IV and Subcutaneous Tocilizumab Biosimilar Approved by the FDA

Fresenius Kabi completes divestment of its Halden, Norway, plant

Empowering Healthcare Innovation: Fresenius Kabi and ESICM Continue Collaboration

Fresenius Closes 2023 With a Strong Fourth Quarter and Expects Accelerated Earnings Growth in 2024 Through Increasing Momentum From #FutureFresenius

A Year of Achievements and Global Collaboration With JUMPstart Clinical Nutrition Alumni Program

A Continuation of Excellence as a Top Employer in 2024

Fresenius Kabi and Mayo Clinic Enter into Multiyear Supply and Service Agreement for the Ivenix® Infusion System

Fresenius Kabi and Formycon Announce FDA Submission Acceptance for Review for Ustekinumab Biosimilar Candidate

Safeguarding Tomorrow: Our Commitment to Fight Antimicrobial Resistance

#FutureFresenius Continues to Provide Positive Momentum

Fresenius Kabi Launches Tyenne®*, the First Approved Tocilizumab Biosimilar in the European Union

Supporting Conscious Choices in Nutritional Care

Gastrointestinal Dysfunction Study Wins Inaugural ESICM Clinical Nutrition Award

Fresenius Kabi and Formycon Announce EMA Submission Acceptance of the Marketing Authorization Application for FYB202, an Ustekinumab Biosimilar Candidate

Tyenne®*, Fresenius Kabi’s Tocilizumab Biosimilar, Receives European Commission Approval

Fresenius Kabi Recognized as a Top Employer in 2023

Virginia Oncology Associates Chooses the Ivenix Infusion System from Fresenius Kabi

Jumpstart Clinical Nutrition Award Winner Announced at ESPEN Congress

Fresenius Kabi and Lupagen Enter Into Strategic Development and Supply Agreement to Bring Cell and Gene Therapies to the Bedside

Paving the Way for the Future of Blood Transfusions

Fresenius Kabi and Formycon Secure U.S. License Date for Proposed Ustekinumab Biosimilar

Heroes Who Save Lives: A Heartfelt Thank You to All Blood and Plasma Donors

Progress on #FutureFresenius

Fresenius Kabi’s Tocilizumab Biosimilar Candidate MSB11456 Receives Positive CHMP Opinion

Fresenius Kabi’s Denosumab Biosimilar Candidate FKS518 Shows Positive Clinical Trial Results

Fresenius Kabi Launches Its Citrate-Free Biosimilar Idacio® (adalimumab-aacf) In the United States

The Gift of Life: A Decision to Donate Blood or Plasma

Fresenius SE Hosts Kabi Capital Markets Day Outlining Pathway Towards Sustainable Value Creation in Line With #FutureFresenius

Fresenius Kabi Awarded Breakthrough Technology Agreement With Premier, Inc. For the Ivenix Infusion System

Fresenius Kabi at the Euroanaesthesia 2023

Fresenius Kabi Offers €100,000 Grant to Advance Nutritional Care in Hospitalized Patients

Fresenius Executing on #FutureFresenius

Help for Communities in Crisis

Fresenius Kabi Launches Single-Needle Option for the Amicus® Extracorporeal Photopheresis Protocol